Cargando…
Current challenges of unresectable stage III NSCLC: are we ready to break the glass ceiling of the PACIFIC trial?
Consolidation anti-programmed death-ligand 1 has become a new standard of care in unresectable stage III non-small cell lung cancer (NSCLC) following chemo-radiotherapy (CTRT), based on the results of two phase III trials. Advances remain however needed, in particular to reduce the risk of distant r...
Autores principales: | Remon, Jordi, Levy, Antonin, Singh, Pawan, Hendriks, Lizza E. L., Aldea, Mihaela, Arrieta, Oscar |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9340398/ https://www.ncbi.nlm.nih.gov/pubmed/35923929 http://dx.doi.org/10.1177/17588359221113268 |
Ejemplares similares
-
Targeted therapies for unresectable stage III non-small cell lung cancer
por: Remon, Jordi, et al.
Publicado: (2021) -
Women in Translational Medicine: Tools to Break the Glass Ceiling
por: Bots, Sophie H., et al.
Publicado: (2018) -
Women in Surgical Fields; Time to break the Glass Ceiling
por: Malik, Tayyaba Gul
Publicado: (2021) -
First-line immune-chemotherapy combination for squamous NSCLC is already a reality
por: Hendriks, Lizza E. L., et al.
Publicado: (2020) -
Breaking the Crystal Ceiling
por: Gebel Berg, Erika
Publicado: (2015)